Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19

NCT06057064 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19, SARS-CoV-2

Interventions

BIOLOGICAL: Biological: AZD3152
BIOLOGICAL: Biological: Placebo

Sponsor

AstraZeneca